



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/615,010-Conf. #8179
				Filing Date	July 7, 2003
				First Named Inventor	Mladen Mercep, et al.
				Art Unit	1642
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	03818/100L651-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
LP	AA	US-2004/0033969-A1	02-19-2004	Burnet et al.	
LP	AB	US-2004/0005641-A1	01-08-2004	Burnet et al.	
LP	AC	US-2001/0006962-A1	07-05-2001	Myhren et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number-Kind Code ⁴ (if known)			
LP	BA	WO	97/41255	11-06-1997	Massachusetts Institute of Technology	
LP	BB	WO	00/64882	11-02-2000	Glaxo Group Ltd.	
LP	BC	WO	99/64040	12-16-1999	Advanced Medicine Inc.	
LP	BD	WO	02/055531	07-18-2002	Pliva d.d.	
LP	BE	WO	03/070254	08-28-2003	Sympore GMBH	
LP	BF	WO	03/070174-A2	08-28-2003	Sympore GMBH	
LP	BG	WO	03/070173-A2	08-28-2003	Sympore GMBH	
LP	BH	EP	0 283 055	09-21-1998	Pliva Pharm & Chem Works	
LP	BI	EP	0 895 999	02-10-1999	Pfizer Products, Inc.	
LP	BJ	GB	2 327 084	01-13-1999	Merck & Co., Inc.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LP	CA	Burnet et al., "Conjugates of biologically active compounds, methods for their preparation and use, formulation, and pharmaceutical applications thereof," U.S. Provisional Application No. 60/357,789, filed February 15, 2002.	
LP	CB	Brandt-Rauf et al., "Fluorescent Assay For Estimating the Binding of Erythromycin Derivatives to Ribosomes," Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington, D.C., 14(1):88-94. (1978).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>G. Piller</i>	Date Considered	8/14/03
--------------------	------------------	-----------------	---------



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/615,010	
			Filing Date	July 7, 2003	
			First Named Inventor	Mladen MERCEP	
			Art Unit	TBA	
			Examiner Name	TBA	
Sheet	1	of	3	Attorney Docket Number	03818/100L651-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
GP	1.	4,474,768	10/02/1984	Bright	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
GP	2.	EP 0984019	03/08/2000	Pfizer Products Inc.	
GP	3.	WO 98/56801	12/17/1998	Pfizer Products Inc.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
GP	4.	Gladue R. P. et al., "In Vitro and In Vivo Uptake of Azithromycin (CP-62,993) by Phagocytic Cells: Possible Mechanism of Delivery and Release at Sites of Infection," <i>Antimicrob. Agents and Chemother.</i> , 33, 1989, 277-282			
GP	5.	Olsen K. M. et al., "Intrapulmonary Pharmacokinetics of Zithromycin in Healthy Volunteers Given Five Oral Doses," <i>Antimicrob. Agents and Chemother.</i> , 40, 1996, 2582-2585			
GP	6.	Mikasa, K. et al., "The anti-inflammatory effect of erythromycin in zymosan-induced peritonitis of mice," <i>J. Antimicrob. Chemother.</i> , 30, 1992, 339-348			
GP	7.	"Discussion, Genomic organization of axolotl 1g genes," <i>J. Immunol.</i> , 159, 1997, 3395-4005			
GP	8.	Takizawa, H. et al., "Erythromycin Modulates IL-8 Expression in Normal and Inflamed Human Bronchial Epithelial Cells," <i>Am. J. Respir. Crit. Care Med.</i> , 156, 1997, 266-271			
GP	9.	Labro, M.T., "Anti-inflammatory activity of macrolides: a new therapeutic potential?" <i>J. Antimicrob. Chemother.</i> , 41, 1998, 37-46			
GP	10.	Denis A. et al., "Synthesis and Antibacterial Activity of HMR 36K47, A New Ketolide Highly Potent Against Erythromycin-Resistant and Susceptible Pathogens," <i>Bioorg. & Med. Chem. Lett.</i> , 9, 1999, 3075-3080			
GP	11.	Agouridas C. et al., "Synthesis and Antibacterial Activity of Ketolides (6-O-Methyl-3-oxoerythromycin Derivatives): A New Class of Antibacterials Highly Potent against Macrolide-Resistant and -Susceptible Respiratory Pathogens," <i>J. Med. Chem.</i> , 41, 1998, 4080-4100			
GP	12.	Sun, Or Y. et al. <i>J. Med. Chem.</i> 2000, 43, 1045-1049			
GP	13.	Denis A. et al., "Synthesis of 6-O-Methyl-Azithromycin and Its Ketolide Analogue via Beckmann Rearrangement of 9(E)-6-O-Methyl-Erythromycin Oxime," <i>Bioorg. & Med. Chem.</i>			

Examiner Signature	<i>G. Pesh</i>	Date Considered	8/5/07
--------------------	----------------	-----------------	--------



PTO/SB/08a/b (06-03)
Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete If Known	
		Application Number	10/615,010
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	July 7, 2003
		First Named Inventor	Mladen MERCEP
		Art Unit	TBA
		Examiner Name	TBA
		Attorney Docket Number	03818/100L651-US1
Sheet	2	of	3

		Left., 8, 1998, 2427-2432	
Gr	14.	Larley et al., "Synthesis of 4"-Deoxy Motilides: Identification of a Potent and Orally Active Prokinetic Drug Candidate, <i>J. Med. Chem.</i> , 38, 1998, 1793-1798	
Gr	15.	Kirst, H.A. et al., "34. Metabolism of macrolides," Bryskier, A. J. et al., Ed. <i>Macrolides, Chemistry, Pharmacology and Clinical Use</i> ; Bryskier, Arnette Blackwell: Paris, 1993; pp 485-491	
Gr	16.	Ma, Z. et al., "Discovery and Development of Ketolides as a New Generation of Macrolide Antimicrobial Agents," <i>Current Medicinal Chemistry - Anti-Infective Agents</i> , 1, 2002, 15-34	
Gr	17.	Pascual A. et al., "Uptake and intracellular activity of ketolide HMR 3647 in human phagocytic and non-phagocytic cells," <i>Clin. Microbiol. Infect.</i> , 7, 2001, 65-69	
Gr	18.	Hand, W. L. et al., "Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes," <i>Int. J. Antimicrob. Agents</i> , 18, 2001, 419-425	
Gr	19.	Amsden, G. W., "Advanced-generation macrolides: tissue-directed antibiotics," <i>Int. J. Antimicrob. Agents</i> , 18, 2001, 11-15	
Gr	20.	Johnson, J. D. et al., "Antibiotic uptake by alveolar macrophages," <i>J. Lab. Clin. Med.</i> , 95, 1980, 429-439	
Gr	21.	Wildfeuer, A. et al., "Uptake of Azithromycin by Various Cells and Its Intracellular Activity under In Vivo Conditions," <i>Antimicrob. Agents Chemother.</i> , 40, 1996, 75-79	
Gr	22.	Scorneaux, B. et al., "Intracellular Accumulation, Subcellular Distribution, and Efflux of Tilmicosin in Chicken Phagocytes," <i>Poult. Sci.</i> , 77, 1998, 1510-1521	
Gr	23.	Mtairag, E. M. et al., "Investigation of dirithromycin and erythromycylamine uptake by human neutrophils in vitro," <i>J. Antimicrob. Chemother.</i> 33, 1994, 523-536	
Gr	24.	Anderson R. et al., "An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent," <i>J. Antimicrob. Chemother.</i> , 22, 1988, 923-933	
Gr	25.	Tasaka, Y. et al., "Rokitamycin Uptake by Alveolar Macrophages," <i>Jpn. J. Antibiot.</i> 41, 1988, 836-840	
Gr	26.	Harf, R. et al., "Spiramycin uptake by alveolar macrophages," <i>J. Antimicrob. Chemother.</i> , 22, 1988, 135-140	
Gr	27.	Suzuki, T. et al., "General and facile method for determination of configuration of steroid-17-yl-methyl glycolates at C-20 based on kinetic examination," <i>Chem. Soc., Perkin Trans. 1</i> , 1998, 3831-3836	
Gr	28.	McLean, H.M. et al., "Novel Fluorinated Antiinflammatory Steroid with Reduced Side Effects: Methyl 9 α -Fluoroprednisolone-16-carboxylate," <i>J. Pharm. Sci.</i> 1994, 83, 476-480	
Gr	29.	Little, R.J. et al., "Soft Drugs Based on Hydrocortisone: The Inactive Metabolite Approach and Its Application to Steroidal Antiinflammatory Agents," <i>Pharm. Res.</i> , 16, 1999, 961-967	
Gr	30.	Kertesz, D.J. et al., "Thiol Esters from Steroid 17 β -Carboxylic Acids: Carboxylate Activation and Internal Participation by 17 α -Acyates," <i>J. Org. Chem.</i> , 51, 1986, 2315-2328	
Gr	31.	Phillipps, G. et al., "Synthesis and Structure - Activity Relationships in a Series of Antiinflammatory Corticosteroid Analogues, Halomethyl Androstane-17 β -carbothioates and 17 β -carboselenoates," <i>J. Med. Chem.</i> 37, 1994, 3717-3729	
Gr	32.	Bright, G.M. et al., "Synthesis, In Vitro and In Vivo Activity of Novel 9-Deoxo-9 α -AZA-9 α -Homoeerythromycin A Derivatives; A new Class of Macrolide Antibiotics, the Azalides" <i>J. Antibiot.</i> , 41, 1998, 1029-1047	

Examiner Signature	<i>G. P. ...</i>	Date Considered	8/5/03
--------------------	------------------	-----------------	--------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known	
		Application Number	10/615,010
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	July 7, 2003
		First Named Inventor	Mladen MERCEP
		Art Unit	TBA
		Examiner Name	TBA
		Attorney Docket Number	03818/100L651-US1
Sheet	3	of	3

33.	Costa, A.M. et al., "Hybrids of macrolides and nucleobases or nucleosides," <i>Tetrahedron Letters</i> , 41, 2000, 3371-3375
34.	Luong et al., "Treatment options for Rheumatoid Arthritis: Celecoxib, Leflunomide, Etanercept, and Infliximab," <i>Ann. Pharmacother.</i> 34, 2000, 743-760
35.	Taketo, M.M., "Cyclooxygenase 2 Inhibitors in Tumorigenesis (Part II)," <i>J. Natl. Cancer Inst.</i> 90, 1998, 1609-1620
36.	Fournier, J., "COX-2 and Colon Cancer: Potential Targets for Chemoprevention," <i>J. Cell Biochem. Suppl.</i> 34, 2000, 97-102
37.	Carswell, E.A., et al., "An endotoxin-induced serum factor that causes necrosis of tumors," <i>Proc. Natl. Acad. Sci. USA</i> 72, 1975, 3666-3670
38.	Elliot, M., et al., "Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis," <i>Lancet</i> 344, 1994, 1105-1110
39.	Mori, L., et al., "Attenuation of Collagen-Induced Arthritis in 55-kDa TNF Receptor Type 1 (TNFR1)-IgG1-Treated and TNFR1-Deficient Mice," <i>J. Immunol.</i> 157, 1996, 3178-3182
40.	Pfeffer, K., et al., "Mice Deficient for the 55 kd Tumor Necrosis Factor Receptor Are Resistant to Endotoxic Shock, yet Succumb to L. monocytogenes Infection," <i>Cell</i> 73, 1993, 457-467
41.	Georgopoulos, J., "Transmembrane TNF Is Sufficient To Induce Localized Tissue Toxicity and Chronic Inflammatory Arthritis in Transgenic Mice," <i>Inflamm.</i> 46, 1996, 86-97
42.	Keffer, J., et al., "Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis," <i>EMBO J.</i> 10, 1991, 4025-4031
43.	Van Assche, et al., "Anti-TNF agents in Crohn's disease," <i>Exp. Opin. Invest. Drugs</i> 9, 2000, 103-111
44.	Romo, D., et al., "Total Synthesis and Immunosuppressive Activity of (-)-Pateamine A and Related Compounds: Implementation of a β -Lactam-Based Macrocyclization," <i>J. Am. Chem. Soc.</i> 120, 1998, 12237-12254

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

W:\03818\100L651-US1\00116797.DOC

Examiner Signature	<i>G. P. ...</i>	Date Considered	8/5/07
-----------------------	------------------	--------------------	--------